What Is Prostamax?
Prostamax is a peptide bioregulator developed by Professor Vladimir Khavinson specifically targeting prostate tissue. Like Libidon, it is designed to restore normal gene expression in aging prostate cells, but with a different peptide sequence providing complementary coverage of prostate cell biology. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Prostate Aging and BPH
Benign prostatic hyperplasia (BPH) affects over 50% of men by age 60 and over 80% by age 80. Its development reflects altered hormonal signaling, increased stromal growth factor signaling, and reduced apoptotic pruning of proliferating prostate cells. Prostamax is designed to normalize prostate cell gene expression, potentially reducing the proliferative imbalance underlying BPH.
Research Applications
Animal studies with Prostamax have shown reduction in prostate gland volume parameters in aged animals, improved histological scores of glandular architecture, and normalization of secretory cell function. Russian clinical research has documented improvements in IPSS (International Prostate Symptom Score) and urinary flow parameters in elderly men receiving Prostamax as part of anti-aging bioregulator protocols. It is frequently combined with Crystagen and Vesilut for comprehensive lower urinary tract support.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications
Borovskaya, T.G., Pakhomova, A.V., Goldberg, V.E., et al., 2013, Modern Research in Inflammation - Effects of short peptides on lymphocyte chromatin in senile subjects
Khavinson, V.K., Lezhava, T.A., Malinin, V.V., 2004, Bulletin of Experimental Biology and Medicine - The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ
Meskhi, T., Khachidze, D., Barbakadze, Sh., et al., 2004, Biofizika - Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)
Dzhokhadze, T.A., Buadze, T.Z., Gaĭozishvili, M.N., et al., 2012, Georgian Medical News - Peptide bioregulators: the new class of geroprotectors
Khavinson, V.K., 2022, Advances in Gerontology - Khavinson development attribution. Existing stored entry reference; Existing stored entry reference
Prostamax is a peptide bioregulator developed by Professor Vladimir Khavinson specifically targeting prostate tissue. Like Libidon, it is designed to restore normal gene expression in aging prostate cells, but with a different peptide sequence providing complementary coverage of prostate cell biology.